Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2.

Abstract

OBJECTIVE The thrombolytic therapy drug, Reteplase, is a domain deletion mutant of tissue plasminogen activator (tPA), comprising the kringle 2 and protease (K2P) domains. Some kringle domains of hemostatic proteins are antiangiogenic and promote apoptosis. The objective of this study was to investigate whether K2P is an angiogenesis inhibitor because of… (More)

8 Figures and Tables

Topics

  • Presentations referencing similar topics